Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Clinuvel Pharmaceuticals Limited
  6. News
  7. Press Releases
    CUV   AU000000CUV3

CLINUVEL PHARMACEUTICALS LIMITED

(CUV)
  Report
End-of-day quote. End-of-day quote Australian Stock Exchange - 10/18
40.48 AUD   -1.53%
10/17CLINUVEL PHARMACEUTICALS : Investor Webinar
PU
10/06CLINUVEL PHARMACEUTICALS : Operations Update Webcast II
PU
10/05Australia shares nearly flat as financials' losses offset tech, healthcare gains
RE
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Communiqués de presse de la société CLINUVEL PHARMACEUTICALS LIMITED
10/17CLINUVEL PHARMACEUTICALS : Investor Webinar
PU
10/06CLINUVEL PHARMACEUTICALS : Operations Update Webcast II
PU
10/04CLINUVEL PHARMACEUTICALS : Progresses DNA Repair Program
PU
09/22CLINUVEL PHARMACEUTICALS : Key Events and Announcements
PU
09/21CLINUVEL PHARMACEUTICALS : Confirms AGM Date
PU
09/13CLINUVEL PHARMACEUTICALS : Presentation H.C. Wainwright Global Investment Conference
PU
08/26CLINUVEL PHARMACEUTICALS : Investor Webinar Financial Results
PU
08/25CLINUVEL PHARMACEUTICALS : Newsletter 4 - August 2021
PU
08/25CLINUVEL PHARMACEUTICALS : Corporate Presentation - FY2021 Results
PU
08/25CLINUVEL PHARMACEUTICALS : Delivers Record Revenues and Profit
PU
08/25CLINUVEL PHARMACEUTICALS : Appendix 4E and Preliminary Financial Report
PU
08/09CLINUVEL PHARMACEUTICALS : Afamelanotide well tolerated by first stroke patients
PU
06/06CLINUVEL PHARMACEUTICALS : Media release - First stroke patient with afamelanotide
PU
06/06CLINUVEL PHARMACEUTICALS : First stroke patient treated with afamelanotide
PU
06/03CLINUVEL PHARMACEUTICALS : Presentation to Jefferies Healthcare Conference
PU
06/02CLINUVEL PHARMACEUTICALS : Newsletter 3 - June 2021
PU
04/28CLINUVEL PHARMACEUTICALS : Appendix 4C - quarterly
PU
04/11CLINUVEL PHARMACEUTICALS : Strategic Update II - April 2021
PU
03/31CLINUVEL PHARMACEUTICALS : Newsletter II - April 2021
PU
03/24CLINUVEL PHARMACEUTICALS : SCENESSE to be assessed in xeroderma pigmentosum variant XPV
PU
03/24CLINUVEL PHARMACEUTICALS : Media Release - CLINUVEL expands DNA Repair Program
PU
03/23CLINUVEL expands DNA Repair Program
GL
03/09CLINUVEL PHARMACEUTICALS : Presentation - Daiwa Investment Conference Tokyo 2021
PU
02/24CLINUVEL PHARMACEUTICALS : Operations Update Webinar Released
PU
02/23CLINUVEL PHARMACEUTICALS : Reports Tenth Consecutive Half Year Profit
PU
02/23CLINUVEL PHARMACEUTICALS : Appendix 4D Half Yearly Report
PU
02/10CLINUVEL PHARMACEUTICALS : SCENESSE Granted Market Access in Israel
PU
01/27CLINUVEL PHARMACEUTICALS : Appendix 4C - quarterly
PU
01/24CLINUVEL PHARMACEUTICALS : Newsletter
PU
2020CLINUVEL PHARMACEUTICALS : Appendix 3G
PU
2020CLINUVEL PHARMACEUTICALS : Newsletter
PU
2020CLINUVEL PHARMACEUTICALS : SCENESSE DNA Repair Study Approved to Commence
PU
2020CLINUVEL PHARMACEUTICALS : Presentation Jefferies Virtual London Healthcare Conference
PU
2020CLINUVEL PHARMACEUTICALS : Chair Letter
PU
2020CLINUVEL PHARMACEUTICALS : Results of Meeting
PU
2020CLINUVEL PHARMACEUTICALS : Chair Address
PU
2020CLINUVEL PHARMACEUTICALS : Managing Directors AGM Presentation
PU
2020CLINUVEL PHARMACEUTICALS : Strategic Update – Executive Summary
PU
2020CLINUVEL PHARMACEUTICALS : Strategic Update - Executive Summary
PU
2020CLINUVEL PHARMACEUTICALS : Strategic Update - Extended
PU
2020CLINUVEL PHARMACEUTICALS : Appendix 4C - quarterly
PU
2020CLINUVEL PHARMACEUTICALS : to Trial Innovative Drug in Stroke
AQ
2020CLINUVEL to Trial Innovative Drug in Stroke
GL
2020CLINUVEL PHARMACEUTICALS : Media Release - CLINUVEL to Trial Innovative Drug in Stroke
PU
2020CLINUVEL PHARMACEUTICALS : afamelanotide for Acute Stroke Patients
PU
2020CLINUVEL PHARMACEUTICALS : Media Release - TGA approves SCENESSE
PU
2020CLINUVEL PHARMACEUTICALS : Australian TGA approves SCENESSE
PU
2020CLINUVEL PHARMACEUTICALS : SCENESSE DNA Repair Update
PU
2020CLINUVEL PHARMACEUTICALS : Further Research Coverage Initiated on CLINUVEL
PU
2020CLINUVEL PHARMACEUTICALS : Presentation - Value in the Vines Investor Conference
PU
2020CLINUVEL PHARMACEUTICALS : Annual General Meeting 2020
PU
2020CLINUVEL PHARMACEUTICALS : Appendix 4G and Corporate Governance Statement
PU
2020CLINUVEL PHARMACEUTICALS : Annual Report to shareholders
PU
2020CLINUVEL PHARMACEUTICALS : Confirms AGM Date
PU
2020First patient dosed in SCENESSE® DNA Repair Program
GL
2020CLINUVEL PHARMACEUTICALS : First patient dosed in SCENESSE® DNA Repair Program
AQ
2020CLINUVEL PHARMACEUTICALS : First patient dosed in SCENESSE DNA Repair Program
PU
2020CLINUVEL PHARMACEUTICALS : Media Release - First patient dosed in SCENESSE DNA Repair
PU
2020CLINUVEL progresses innovative DNA Repair Program
GL
2020CLINUVEL PHARMACEUTICALS : progresses innovative DNA Repair Program
AQ
2020CLINUVEL PHARMACEUTICALS : progresses innovative DNA Repair Program
PU
2020CLINUVEL PHARMACEUTICALS : SCENESSE in DNA Repair
PU
2020CLINUVEL Opens VALLAURIX R&D Centre In Singapore
GL
2020CLINUVEL PHARMACEUTICALS : Corporate Presentation - 2020 Full Year Results
PU
2020CLINUVEL PHARMACEUTICALS : Declares Full Year Dividend
PU
2020CLINUVEL PHARMACEUTICALS : Appendix 4E and Preliminary Financial Report
PU
2020CLINUVEL PHARMACEUTICALS : Full Year Results
PU
2020CLINUVEL PHARMACEUTICALS : Appendix 4C – quarterly
PU
2020CLINUVEL PHARMACEUTICALS : Corporate Update
PU
2020CLINUVEL PHARMACEUTICALS : PRÉNUMBRA® - CLINUVEL's Second Afamelanotide Formulation
AQ
2020CLINUVEL PHARMACEUTICALS : Lapse and Forfeit of Unlisted Conditional Performance Rights
PU
2020MEDIA RELEASE : SCENESSE® to be prescribed in China
PU
2020CLINUVEL PHARMACEUTICALS : SCENESSE® to be Prescribed in China
AQ
2020CLINUVEL PHARMACEUTICALS : First US Patients to be treated with SCENESSE®
PU
2020CLINUVEL PHARMACEUTICALS : Innovative drug launched for rare, isolating, “light into..
AQ
1  2  3  4Next
Upcoming event on CLINUVEL PHARMACEUTICALS LIMITED